Activated Cytotoxic Compounds with Self-Immolative Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer treatments face challenges such as nonselective toxicity, inefficient drug delivery, and resistance to multidrug-resistant tumor cells, limiting their efficacy and increasing side effects.
Innovation Solution
Development of activated cytotoxic compounds comprising an activator, a spacer linker, a self-immolative linker, and cytotoxic drugs like amino-substituted (E)-2,6-dialkoxystryyl 4-substituted benzenesulfones, amino- and hydroxy-substituted styrylsulfonanilides, and substituted phenoxy- and phenylthio-styrylsulfone derivatives, which are attached to targeting molecules like antibodies to enhance tumor specificity and reduce systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional chemotherapies are used, then cytotoxic effect is achieved, but nonselective toxicity to normal tissues occurs
Solution Approach 1:
The cytotoxic compound is segmented into distinct functional modules: a cytotoxic warhead, a self-immolative linker, and a targeting molecule attachment site. This segmentation allows the cytotoxic agent to be delivered selectively to tumor cells via the targeting molecule while remaining inactive during circulation, thereby achieving cytotoxic effect without systemic toxicity to normal tissues.
Solution Approach 2:
A self-immolative linker serves as an intermediary between the targeting molecule and the cytotoxic compound. This intermediary remains intact during circulation, preventing premature activation, and then undergoes spontaneous degradation upon reaching the target site, releasing the active cytotoxic agent selectively at the tumor location while protecting normal tissues from exposure.
2Productivity
If highly cytotoxic compounds are used, then tumor regression is enhanced, but systemic toxicity increases
Solution Approach 1:
The cytotoxic compound is pre-conjugated to a targeting molecule and equipped with a self-immolative linker before administration. This preliminary preparation ensures that the highly potent cytotoxic agent is delivered directly to tumor cells via the targeting molecule's specificity, allowing strong tumor regression effects while the linker prevents premature activation and systemic toxicity during circulation and distribution.
3Measurement precision
If cytotoxic compounds are attached to targeting molecules, then tumor specificity is improved, but drug release efficiency may be reduced
Solution Approach 1:
The self-immolative linker is designed to automatically degrade through spontaneous chemical reactions (such as retro-aldol condensation or other self-immolative mechanisms) upon reaching the target site or upon triggering by specific tumor microenvironment conditions. This self-service mechanism eliminates the need for complex external activation systems, maintaining high tumor specificity while enabling efficient autonomous drug release without adding significant system complexity.
Data Source
AI summary
Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions.